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Human papillomavirus (HPV) hybrid virus-like particles (VLPs) were prepared using complementary regions of the major
capsid L1 proteins of HPV-11 and -16. These hybrid L1 proteins were tested for assembly into VLPs, for presentation and
mapping of conformational neutralizing epitopes, and as immunogens in rabbits and mice. Two small noncontiguous
hypervariable regions of HPV-16 L1, when replaced into the HPV-11 L1 backbone, produced an assembly-positive hybrid L1
which was recognized by the type-specific, conformationally dependent HPV-16 neutralizing monoclonal antibody (N-MAb)
H16.V5. Several new N-MAbs that were generated following immunization of mice with wild-type HPV-16 L1 VLPs also
recognized this reconstructed VLP, demonstrating that these two hypervariable regions collectively constituted an immu-
nodominant epitope. When a set of hybrid VLPs was tested as immunogens in rabbits, antibodies to both HPV-11 and -16
wild-type L1 VLPs were obtained. One of the hybrid VLPs containing hypervariable FG and HI loops of HPV-16 L1 replaced
into an HPV-11 L1 background provoked neutralizing activity against both HPV-11 and HPV-16. In addition, conformationally
dependent and type-specific MAbs to both HPV-11 and HPV-16 L1 VLP were obtained from mice immunized with hybrid L1
VLPs. These data indicated that hybrid L1 proteins can be constructed that retain VLP-assembly properties, retain
type-specific conformational neutralizing epitopes, can map noncontiguous regions of L1 which constitute type-specific
conformational neutralizing epitopes recognized by N-MAbs, and trigger polyclonal antibodies which can neutralize anti-
genically unrelated HPV types. © 2001 Elsevier ScienceINTRODUCTION
Papillomavirus virus-like particles (VLPs) have proved
to be useful reagents for the induction of protective
immunity in animal models (Breitburd et al., 1995; Jansen
et al., 1995; Suzich et al., 1995; Christensen et al., 1996c;
Kirnbauer et al., 1996; Stanley et al., 2001) and for sero-
logical reagents (Carter et al., 1993; Rose et al., 1994;
Kirnbauer et al., 1994; Heim et al., 1995; Wikstro¨m et al.,
1995; LeCann et al., 1995; Strickler et al., 1997) and are
currently in clinical trials for the prevention of human
papillomavirus (HPV) infections (Zhang et al., 2000;
Schiller and Hidesheim, 2000; Evans et al., 2001; Harro et
al., 2001; Pastrana et al., 2001). Predominant neutralizing
epitopes on papillomaviruses, however, target conforma-
tional sites that are located on the surface-exposed hy-
pervariable loop structures of the virion (Chen et al.,
2000). In addition, the neutralizing antibodies induced by
immunization with VLPs or virions detect immunodomi-
nant, conformational epitopes which are highly type spe-
cific (Christensen and Kreider, 1990; Rose et al., 1994;
Hines et al., 1995; Roden et al., 1996b). Cross-reactive
1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (717) 531-5634. E-mail: ndc1@psu.edu.
0042-6822/01 $35.00
© 2001 Elsevier Science
All rights reserved.
324anti-capsid antibodies are generally nonneutralizing un-
less reactive to closely related HPV types (Christensen et
al., 1996b; Roden et al., 1996a,b, 2000; White et al., 1999).
A primary requirement for the analysis of papillomavi-
rus VLP vaccines has been the need to develop virus-
neutralizing assays. Thus, characterization of conforma-
tional neutralizing epitopes on papillomavirus capsids
was initially impeded by lack of stocks of infectious HPVs
and lack of infectivity assays to determine virus neutral-
ization. Early neutralization assays were limited to those
virus types that could be propagated in the athymic
mouse xenograft system (Kreider et al., 1985). This model
requires stocks of infectious HPV, specialized animal
facilities, and sources of human genital tissues (Chris-
tensen and Kreider, 1990; Bonnez et al., 1992, 1998;
Christensen et al., 1997; Brown et al., 1998). Recent
innovations included transient in vitro infection assays
using xenograft-derived virus (Smith et al., 1993, 1995;
White et al., 1998), organotypic raft culture-derived viri-
ons (Meyers et al., 1992, 1997; Frattini et al., 1997), and
infectious “pseudovirions” (Roden et al., 1996a; Unckell et
al., 1997; Touze and Coursaget, 1998; Yeager et al., 2000).
Assays are now in place to assess virus neutralization
for most HPV types.
Given the high level of type-specific neutralizing anti-
325HYBRID HPV L1 VLPsbody responses generated by VLPs prepared from wild-
type HPV L1 sequences, there is a need to develop
additional strategies for the induction of cross-protective
immunity and/or immunity to antigenically unrelated HPV
types. Current vaccine strategies are focused on using a
mixture of one or more VLPs constructed from wild-type
L1 genes of clones of certain HPV types such as HPV-11
and -16 (Zhang et al., 2000; Schiller and Hidesheim, 2000;
Evans et al., 2001; Harro et al., 2001; Pastrana et al.,
2001). An alternative strategy that has yet to be tested for
papillomavirus vaccines involves production of hybrid
recombinant viruses and/or VLPs that contain capsid
antigen determinants from multiple different HPV types.
This strategy has been used successfully to construct
vaccines for the induction of simultaneous protective
immunity against respiratory syncytial virus and human
parainfluenza virus type 3 (Schmidt et al., 2001) and to
map epitopes of swine vesicular disease viruses (Dekker
et al., 2000).
The purpose of this study was twofold: first to charac-
terize and reconstruct HPV-16 type-specific conforma-
tional neutralizing epitopes and second to utilize this
information on epitope mapping to develop reagents that
could generate polyclonal neutralizing antibody re-
sponses to antigenically unrelated HPV types. This was
achieved by employing a series of hybrid L1 molecules
that retained VLP assembly properties. We first prepared
hybrid L1 proteins by fusing large domains of HPV-11
and -16 L1 to identify immunoreactivity regions of neu-
tralizing monoclonal antibodies (N-MAbs). For more re-
fined mapping of conformational epitopes of the HPV-16
N-MAbs, a second set of hybrid L1 proteins was pre-
pared using small hypervariable regions of HPV-16 L1
that were substituted into the HPV-11 L1 backbone. Re-
construction of conformational epitopes recognized by
type-specific HPV-16 N-MAbs was achieved for several
independently targeting N-MAbs. The second goal of the
study was to determine whether hybrid VLPs were ca-
pable of inducing polyclonal neutralizing antibodies to
two (or more) distinct HPV types. We found that VLPs
prepared from one of three hybrid L1 proteins containing
regions of HPV-11 and -16 L1 induced virus-neutralizing
antibodies to both HPV types.
RESULTS
Construction of hybrid VLPs and ELISA reactivity of a
panel of MAbs
An additional set of MAbs reactive to VLPs of HPV-16
L1 (to complement a previous set prepared in our labo-
ratory; Christensen et al., 1996a) was prepared using an
HPV-16 L1 obtained from CasKi cells as described under
Materials and Methods. Thirteen MAbs that showed re-
activity to intact HPV-16 L1 VLPs were obtained. Twelve
of these recognized surface, conformational epitopes;
binding was not observed to denatured VLP antigen(Table 1). One of 13 (H16.15G) recognized a linear
epitope. None of these MAbs recognized HPV-11 VLP
antigen. These additional MAbs were prepared so that
we had a large set of MAb probes for the fine analysis of
different conformational epitopes on intact HPV-16 L1
VLPs.
To initially map the reactivity patterns of these confor-
mationally dependent MAbs, a set of VLPs was prepared
from several HPV-11/16 hybrid L1 molecules (Fig. 1). The
ELISA binding results of these MAbs are summarized in
Table 1. All conformationally dependent MAbs reacted
with VLPs of either construct H11:16[172–505] or the
reciprocal construct H16:11[171–505] (Table 1). The pre-
dominant reactivity was to VLPs of construct H11:16[172–
505], which was also recognized by three previously
described HPV-16-reactive N-MAbs (H16.V5, E70, and
U4; Christensen et al., 1996a). These data indicated that
the C-terminal region of HPV-16 L1, from amino acid (aa)
172 to 505, is immunodominant. Three of the new con-
formationally dependent MAbs (H16.7E, 9A, and 16K)
recognized H16:11[171–505] VLPs but not H11:16[172–
505] VLPs, demonstrating that these latter MAbs recog-
nized the less immunogenic region of HPV-16 L1 from aa
1 to 168. Two of the MAbs (H16.8B and 11B) appeared to
be reactive to VLPs of both H11:16[172–505] and H16:
11[171–505], suggesting that they recognize a composite
epitope. These latter two MAbs also recognized HPV-16
VLPs, but not HPV-11 VLPs, further indicating that while
HPV-11 sequences can partially compensate for the
epitope, the uniqueness of the epitope is defined by
HPV-16 sequences. Attempts to map any of the confor-
mationally dependent MAbs using fragments of L1 is not
possible because such fragments do not assemble into
VLPs (Li et al., 1997).
A second important observation regarding the reactiv-
ity patterns of these MAbs was that H11:16[172–505]
VLPs were recognized by both H16.V5 and H11.B2, and
H16:11[171–505] VLPs were recognized by both H16.7E
and H11.H3. These four N-MAbs show virus type-specific
neutralizing activity to HPV-16 and HPV-11, respectively
(see below), thus demonstrating that the hybrid VLPs
retained conformationally dependent neutralizing
epitopes for two antigenically unrelated HPV types.
Whereas HPV-16 VLPs which present an HPV-11 epitope
have been previously described, the level of HPV-11 MAb
binding to these VLPs was clearly reduced relative to
wild-type HPV-11 VLPs (Ludmerer et al., 1997). In con-
trast, the hybrid VLPs described in this work facilitate a
level of MAb binding comparable to wild-type VLPs for
both HPV-11 and HPV-16 MAbs.
The ELISA binding activity of panels of MAbs against
the hybrid VLPs provided initial characterization of the
regions of the L1 that were recognized by conformation-
ally dependent N-MAbs. Previously, it was demonstrated
that the major immunogenic sites recognized by several
326 CHRISTENSEN ET AL.conformationally dependent N-MAbs mapped to surface-
exposed hypervariable regions of the L1 (Chen et al.,
2000; Ludmerer et al., 1996, 1997; Roden et al., 1997;
White et al., 1998). Therefore, we generated VLPs that
contained hypervariable loop replacements to fine-map
the binding sites (Fig. 1). The panels of HPV-16-reactive
MAbs were tested for reactivity to VLPs prepared from
several hybrid L1 proteins (Fig. 1) in which hypervariable
regions of HPV-16 L1 were replaced into the HPV-11 L1
backbone (Table 1). Construct H11:16[38–65], which con-
sisted of replacement of aa 38–65 and includes the BC
loop (Chen et al., 2000) by 16 L1 residues, bound one of
the conformationally reactive HPV-16 type-specific MAbs
(H16.7E) at levels equivalent to wild-type HPV-16 L1 VLPs
(Table 1). VLPs from construct H11:16[266–297], which
contains the FG loop (Chen et al., 2000), however, re-
trieved binding of a total of four of the conformationally
dependent HPV-16 type-specific MAbs including H16.V5,
2F, 5A, and 6F. These data suggest that region 266–297
is immunodominant over the epitope described by resi-
dues 38–65. Importantly, binding by these MAbs was
increased when VLPs of construct H11:16[266–97 1
339–65] (hereafter described as H11:16[FG 1 HI]), in
which two noncontiguous hypervariable regions of
HPV-16 L1 containing the FG and the HI loops (Chen et
al., 2000) were replaced into HPV-11 L1, were employed
T
ELISA Reactivity of Monoclonal Antibo
MAb 16 16 (D)b 11
H11:16-
[172–505]
H16.V5c 0.811 (0.003) 0.005 (0.0) 0.012 (0.001) 1.266 (0.001)
H16.E70c 0.274 (0.008) N.T.d 0.014 (0.001) 0.218 (0.016)
H16.U4c 0.163 (0.005) N.T. 0.014 (0.000) 0.132 (0.029)
H16.1A 0.985 (0.050) 0.017 (0.001) 0.016 (0.002) 1.256 (0.048)
H16.2F 0.905 (0.020) 0.015 (0.005) 0.015 (0.000) 1.174 (0.017)
H16.3A 0.398 (0.011) 0.000 (0.0) 0.016 (0.001) 0.476 (0.007)
H16.4A 0.704 (0.019) 0.172 (0.169) 0.013 (0.001) 0.851 (0.033)
H16.5A 1.075 (0.029) 0.038 (0.022) 0.014 (0.001) 1.400 (0.047)
H16.6F 0.927 (0.037) 0.001 (0.0) 0.015 (0.001) 1.085 (0.029)
H16.7E 0.670 (0.027) 0.006 (0.007) 0.015 (0.000) 0.033 (0.002)
H16.8B 0.317 (0.024) 0.032 (0.014) 0.048 (0.001) 0.361 (0.021)
H16.9A 0.176 (0.019) 0.021 (0.0) 0.022 (0.001) 0.024 (0.001)
H16.11B 0.149 (0.001) 0.003 (0.0) 0.025 (0.003) 0.312 (0.010)
H16.14J 0.816 (0.057) 0.000 (0.000) 0.013 (0.001) 1.077 (0.045)
H16.15G 0.185 (0.004) 1.411 (0.010) 0.014 (0.001) 0.634 (0.005)
H16.16K 0.067 (0.004) 0.021 (0.0) 0.014 (0.000) 0.014 (0.001)
H16.J4 N.T. 2.000 (0.0) 0.016 (0.001) N.T.
H11.B2 N.T. N.T. 2.000 (0.0) 2.000 (0.0)
H11.H3 N.T. N.T. 2.000 (0.0) 0.015 (0.003)
(—)e 0.015 (0.004) 0.003 (0.004) 0.011 (0.000) 0.049 (0.005)
a ELISA values represent mean (SD) of OD readings of duplicate EL
b Denatured VLP antigen.
c N-MAbs previously prepared against HPV-16 L1 VLPs (Christensen
d Not tested.
e No VLP antigen.(see Fig. 1). The increased binding was particularly no-
ticeable for MAbs H16.V5, 1A, and H263.A2 (Tables 1 and2, Fig. 2). When N-MAb H16.V5 was tested for binding to
different VLPs, H11:16[FG 1 HI] VLPs retrieved wild-type
binding, whereas H11:16[266–297] VLPs were two orders
of magnitude less reactive and thus only partially re-
trieved binding reactivity (Fig. 2). These data suggested
that N-MAb H16.V5 recognized a composite epitope in
which sequences at 339–365 influence or stabilize bind-
ing to sequences at 266–297. A similar composite
epitope has been described for some HPV-11 N-MAbs
(Ludmerer et al., 2000).
All HPV-16 reactive MAbs were tested for reactivity to
VLPs prepared from an HPV-16 L1 in which aa 50 was
mutated from Phe to Leu (White et al., 1999). These
investigators had demonstrated that several conforma-
tionally dependent HPV-16-dependent MAbs, including
H16.V5 and H16.E70, failed to bind to this mutant VLP.
These observations were confirmed in our hands (Table
1). All of the new conformationally dependent HPV-16
type-specific MAbs except H16.9E and 11B also lost
binding to the Leu50 mutant VLP. In contrast, HPV-16
MAbs that were shown previously to recognize surface
linear epitopes (Christensen et al., 1996a) were reactive
to this mutant VLP (Table 1, MAb H16.J4; additional data
not shown). These results suggest that a leucine substi-
tution at residue 50 exerts a more global effect on VLP
enerated against HPV-16 L1wt VLPsa
VLP
11-
505]
H11:16-
[266–297]
H11:16-
[266–97 1 339–65]
H11:16-
[38–65] Leu50
.0) 0.218 (0.018) 0.952 (0.098) 0.014 (0.001) 0.000 (0.000)
.0) 0.015 (0.001) 0.035 (0.001) 0.014 (0.000) 0.006 (0.006)
.0) 0.012 (0.001) 0.016 (0.001) 0.014 (0.001) 0.003 (0.001)
.0) 0.086 (0.004) 1.034 (0.042) 0.015 (0.002) 0.005 (0.003)
.0) 0.619 (0.044) 1.259 (0.031) 0.015 (0.001) 0.003 (0.000)
.005) 0.015 (0.003) 0.031 (0.013) 0.019 (0.005) 0.006 (0.004)
.011) 0.016 (0.001) 0.116 (0.029) 0.012 (0.001) 0.002 (0.000)
.0) 1.077 (0.083) 1.483 (0.028) 0.012 (0.000) 0.001 (0.001)
.0) 0.684 (0.006) 1.096 (0.066) 0.015 (0.001) 0.001 (0.001)
.011) 0.013 (0.001) 0.015 (0.000) 1.266 (0.029) 0.011 (0.006)
.018) 0.052 (0.011) 0.029 (0.001) 0.043 (0.001) 0.003 (0.001)
.015) 0.024 (0.000) 0.021 (0.003) 0.035 (0.004) 0.235 (0.018)
.021) 0.037 (0.006) 0.023 (0.000) 0.029 (0.001) 0.560 (0.009)
.0) 0.013 (0.001) 0.050 (0.006) 0.015 (0.002) 0.002 (0.001)
.0) 0.014 (0.000) 0.016 (0.001) 0.014 (0.001) 0.017 (0.001)
.022) 0.016 (0.001) 0.016 (0.000) 0.014 (0.002) 0.005 (0.001)
. 0.354 (0.005) 0.957 (0.041) 0.014 (0.002) 0.417 (0.100)
.001) 2.000 (0.0) 1.501 (0.026) 1.820 (0.255) N.T.
.033) N.T. N.T. N.T. N.T.
.000) 0.012 (0.000) 0.015 (0.001) 0.018 (0.008) 0.004 (0.005)
lls. Underlined values are considered positive for MAb binding.
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et al.,structure, which can impact the binding of antibodies
that recognize discrete surface conformational epitopes.
eI and
327HYBRID HPV L1 VLPsImmunization with hybrid VLPs induces mixtures of
HPV type-specific MAbs
The results discussed above also demonstrated that
several VLPs prepared from hybrid L1 molecules con-
FIG. 1. Hybrid and mutant L1 constructs used in this study. Amino ac
from published L1 sequences. Alignment was conducted using the D
Engineered restriction enzyme sites for replacement of aa 266–297 for
SpeI; for replacement of aa 38–65 for construct H11:16[38–65] were Nh
365] and H11:16[266–97 1 339–65] were MluI and PmlI.
T
ELISA of Monoclonal Antibodies Raised against
MAb 16 16 (D)b 11 11 (D)b 6
H263.A2c 1.331 (0.076) 0.002 (0.003) 0.000 (0.001) 0.004 (0.004) 0.000 (0.001)
H263.C3 0.139 (0.057) 0.000 (0.000) 1.034 (0.027) 0.008 (0.002) 0.789 (0.006)
H263.D1 0.050 (0.012) 0.000 (0.001) 1.158 (0.062) 0.007 (0.001) 0.921 (0.077)
H263.F4 0.008 (0.003) 0.001 (0.001) 0.185 (0.001) 0.012 (0.005) 0.168 (0.032)
H263.G2 0.000 (0.002) 0.004 (0.001) 0.830 (0.023) 0.008 (0.001) 0.000 (0.001)
H263.H9 0.000 (0.000) 0.002 (0.001) 0.222 (0.007) 0.008 (0.002) 0.099 (0.003)
H175.A1c 0.192 (0.013) 0.568 (0.075) 0.005 (0.002) 0.008 (0.001) 0.000 (0.001)
H11.B2 0.000 (0.002) N.T.d 2.000 (0.0) N.T. 0.011 (0.001)
H11.H3 0.000 (0.002) 0.003 (0.000) 2.000 (0.0) 0.008 (0.000) N.T.
H16.V5 1.203 (0.021) 0.004 (0.003) 0.008 (0.004) 0.007 (0.000) N.T.
H16.J4 N.T. 1.784 (0.305) N.T. 0.019 (0.011) N.T.
H6.B10 N.T. N.T. N.T. N.T. 0.567 (0.136)
H6.C6 N.T. 0.002 (0.001) N.T. 0.569 (0.223) 2.000 (0.0)
(—)e 0.000 (0.001) 0.000 (0.001) 0.004 (0.000) 0.001 (0.0) 0.001 (0.002)
a ELISA values represent mean (SD) of OD readings of duplicate EL
b Denatured VLP antigen.
c MAbs designated with the prefix H263 were generated against
H16:11[171–505] VLPs.
d Not tested.
e No VLP antigen.tained neutralizing epitopes of both HPV-11 and HPV-16
(Table 1). It was important to determine whether these
hybrid VLPs could induce neutralizing antibodies to wild-
type virus, as this would suggest possibilities to elicit
designations represent the positional numbers for each L1 sequence
ware analysis program DNAMAN (Lynnon BioSoft, Quebec, Canada).
cts H11:16[266–297] and H11:16[266–297 1 339–65] were NgoMI and
BspEI; and for replacement of aa 339–365 for constructs H11:16[339–
VLPs, H11:16[172–505] and H16:11[171–505]a
VLP
6-
05]
H16:11-
[171–505]
H11:16-
[266–297]
H11:16-
[266–97 1 339–65]
H11:16-
[38–65] Leu50
.026) 0.006 (0.007) 0.000 (0.002) 1.068 (0.165) 0.000 (0.000) 0.000 (0.001)
.021) 0.009 (0.002) 0.103 (0.023) 0.346 (0.008) 0.425 (0.070) 0.153 (0.006)
.042) 0.007 (0.002) 0.196 (0.023) 0.435 (0.063) 0.562 (0.002) 0.038 (0.003)
.001) 0.008 (0.001) 0.015 (0.007) 0.036 (0.004) 0.066 (0.013) 0.022 (0.000)
.037) 0.007 (0.002) 0.254 (0.014) 1.026 (0.026) 0.000 (0.001) 0.000 (0.001)
.002) 0.008 (0.001) 0.023 (0.002) 0.047 (0.001) 0.013 (0.001) 0.005 (0.007)
.001) 0.319 (0.010) 0.004 (0.003) 0.003 (0.001) 0.000 (0.003) 0.285 (0.009)
.055) 0.008 (0.000) 1.409 (0.041) 2.000 (0.0) 2.000 (0.0) 0.000 (0.001)
.001) 0.197 (0.011) N.T. 0.006 (0.004) N.T. 0.001 (0.003)
.001) 0.017 (0.008) 0.196 (0.004) 0.868 (0.075) N.T. 0.000 (0.001)
. N.T. N.T. N.T. N.T. N.T.
. N.T. N.T. N.T. N.T. N.T.
. N.T. N.T. N.T. N.T. N.T.
.001) 0.003 (0.001) 0.003 (0.001) 0.002 (0.000) 0.000 (0.001) 0.001 (0.001)
lls. Underlined values are considered positive for MAb binding.
172–505] VLPs; MAbs with the prefix H175 were generated againstid (aa)
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construABLE 2
Hybrid
H11:1
[172–5
0.995 (0
0.266 (0
0.397 (0
0.048 (0
0.477 (0
0.057 (0
0.008 (0
0.946 (0
0.003 (0
1.049 (0
N.T
N.T
N.T
0.001 (0
ISA we
H11:16[
328 CHRISTENSEN ET AL.neutralizing responses to multiple HPV types using VLPs
prepared from single hybrid L1 molecules. Mice were
immunized with VLPs of either H11:16[172–505] (desig-
nated by the MAb prefix H263) or H16:11[171–505] (des-
ignated by the MAb prefix H175) to determine whether
type-specific MAbs recognizing either wild-type HPV-11
or -16 L1 VLPs could be induced. MAbs were screened
and selected for reactivity to the hybrid VLPs and then
retested for reactivity to wild-type HPV-11, -6, and -16
VLPs. Several HPV type-specific MAbs were detected
(Table 2). Immunization with H11:16[172–505] VLPs pro-
duced one HPV-16 type-specific MAb, H263.A2, which
showed a very similar binding pattern to H16.V5. A set of
five HPV-11-reactive MAbs was produced in the same
immunization. Four of these MAbs also recognized
HPV-6 but not HPV-16 L1 VLPs, demonstrating limited
cross-reactivity as seen for other 6/11 reactive MAbs
(Christensen et al., 1996b). Two of the HPV-11 reactive
MAbs (H263.G2 and H9) lost binding to VLPs of hybrid
construct H11:16[38–65], indicating that the hypervari-
FIG. 2. Titration of N-MAb H16.V5 against VLPs produced from
wild-type and hybrid HPV-11/16 L1 genes. Ascites was tested at 10-fold
dilutions in duplicate for VLPs from HPV16 L1 VLPs (F), hybrid con-
struct H11:16[266–297] (E), hybrid construct H11:16[339–365] () and
hybrid construct H11:16[266–97 1 339–65] (). ELISA values represent
the means (6SD) of duplicate ELISA wells for each antibody dilution
point.
T
Rabbit Polyclonal Antibody Respo
Rabbit
No.
Immunizing
VLPa
Serum
dilutionb
16 VLP O
(mean 6 S
C0806 HPV-11 L1 wt 1:103 0.082 (0.00
H0367 HPV-16 L1 wt 1:106 0.843 (0.11
I0660 H11:16[266–97 1 339–65] 1:104 0.453 (0.03
I0661 H16:11[171–505] 1:104 0.501 (0.12
I0662 H11:16[172–505] 1:104 0.263 (0.12
a VLPs used to immunize rabbits.
b Dilution of sera at which ELISA readings are recorded.
c ELISA titer of sera (dilution at which ELISA readings are estimated to beable region between aa 38 and 65 was an important
antigenic region for these MAbs. Interestingly, there
were no MAbs that uniquely recognized only the hybrid
VLPs. The results suggest that the major conformational
epitopes are physically distinct and, within the context of
a VLP, can be presented or altered with little impact on
other distinct, conformational epitopes.
Induction of polyclonal antibody to hybrid VLPs
Rabbits were immunized with VLPs prepared from the
hybrid L1 constructs H11:16[172–505], H16:11[171–505],
and H11:16[FG 1 HI], as well as with wild-type HPV-11
and -16 L1. Sera were tested by ELISA for reactivity to
HPV-16 and -11 L1 VLPs and the data are shown in Table
3. Sera from rabbits immunized with wild-type VLPs gen-
erated antibody responses that were predominantly
type-specific as found by others (Rose et al., 1994; Roden
et al., 1996b; Hines et al., 1995). In contrast, antibody
titers of sera from rabbits immunized with the hybrid
VLPs were similar for both HPV-16 and -11 L1 VLPs
(Table 3).
Virus neutralization
Neutralizing activity of the polyclonal antibodies (PAbs)
and MAbs was assessed using the pseudovirion neu-
tralization assay (Yeager et al., 2000), and the results are
summarized in Table 4.
Rabbit polyclonal antisera generated against VLPs of
three hybrid and two wild-type L1s were tested for neu-
tralizing activity to HPV-11 and -16 pseudovirions. Wild-
type HPV-11 and -16 L1 VLPs induced strong neutralizing
activity against either HPV-11 or HPV-16, respectively, as
previously found by others (Rose et al., 1994; Roden et
al., 1996b; Yeager et al., 2000). H11:16[FG 1 HI] VLPs
generated polyclonal antisera which neutralized both
HPV-11 and HPV-16 (Table 4). In contrast, sera from
rabbits immunized with H11:16[172–505] or H16:11[171–
505] VLPs were type-specific in neutralizing activity, neu-
tralizing predominantly either HPV-11 or HPV-16, respec-
tively, but not both. Results were qualitatively the same in
HPV-11 and -16 L1 VLP Antigens
11 VLP OD
(mean 6 SD)b
16 titer
(12 max OD reading)
c
11 titer
(12 max OD reading)
c
0.870 (0.033) 1021 1023.3
0.117 (0.018) 1026.5 1024
0.607 (0.112) 1:1023 1:1024
0.545 (0.096) 1:1023 1:1023.5
0.323 (0.049) 1:1022.4 1:1023.3ABLE 3
nse to
D
D)b
8)
7)
)
3)
8)1
2 maximum OD readings).
329HYBRID HPV L1 VLPstwo different HPV-11 neutralization assays, the transient
in vitro infection assay (Smith et al., 1993; Ludmerer et al.,
2000) or the HPV-11 pseudovirion neutralization assay
(Yeager et al., 2000; additional results not shown). These
data demonstrated that appropriately constructed hybrid
VLPs could induce neutralizing antibodies against anti-
genically unrelated HPV types.
Most of the new HPV-16 reactive MAbs raised to
wild-type HPV-16 L1 VLPs were strongly neutralizing
(neutralizing titers typically were between 1:100 and
1:500 for cell culture supernatants and .1:10,000 with
ascites for MAbs H16.7E and 9A). These results confirm
other studies which found that most conformationally
dependent mouse MAbs were virus neutralizing (Chris-
tensen et al., 1990, 1996a,b).
MAbs prepared from mice immunized with hybrid H11:
16[172–505] VLPs showed type-specific reactivity to ei-
ther HPV-11 or -16 L1 VLPs. Four of five HPV-11-reactive
MAbs also recognized intact HPV-6 L1 VLPs, demon-
strating limited cross-reactivity. All MAbs that were
HPV-11 L1 VLP-reactive were virus neutralizing for
HPV-11 (Table 4), and although further testing was not
conducted, we would expect the four HPV-6/11 cross-
reactive MAbs to also neutralize HPV-6 pseudovirions.
T
Virus Neutralization of Mous
MAb or sera Immunizing VLP VLP rea
C0806b HPV-11 L1 HPV-11
H0367b HPV-16 L1 HPV-16
I0660b H11:16[266–97 1 339–65] HPV-11
I0661b H16:11[171–505] HPV-11
I0662b H11:16[172–505] HPV-11
H16.1A HPV-16 L1 HPV-16
H16.2F HPV-16 L1 HPV-16
H16.3A HPV-16 L1 HPV-16
H16.4A HPV-16 L1 HPV-16
H16.5A HPV-16 L1 HPV-16
H16.6F HPV-16 L1 HPV-16
H16.7Ed HPV-16 L1 HPV-16
H16.9Ad HPV-16 L1 HPV-16
H263.A2 H11:16[172–505] HPV-16
H263.C3 H11:16[172–505] HPV-11
H263.D1 H11:16[172–505] HPV-11
H263.F4 H11:16[172–505] HPV-11
H263.G2 H11:16[172–505] HPV-11
H263.H9 H11:16[172–505] HPV-11
H11.B2 HPV-11 virions HPV-11
a Dilution of sera, cell culture supernatant, or ascites that was neutra
MAb tested was 1:100.
b Rabbit sera (preimmune sera were nonneutralizing at 1:100 dilutio
c Not tested.
d Ascites fluid.These data provided additional evidence that hybrid
VLPs are capable of inducing virus neutralizing activity.DISCUSSION
The major goals of this study were to determine
whether hybrid L1 molecules prepared from HPV-11 and
-16 L1 sequences could assemble into VLPs, be used to
detect and map conformational neutralizing epitopes of
N-MAbs, and elicit multiple type-specific neutralizing re-
sponses. The strategy was to generate full-length L1
proteins so that all the conserved features of the L1 aa
sequence were retained, thereby maximizing the oppor-
tunity for the L1 to retain self-assembly properties. The
outcome of these initial studies using hybrid HPV11/16
L1 proteins confirmed the utility of this approach. We
were able to reconstruct HPV-16 type-specific neutraliz-
ing epitopes into an HPV-11 L1 backbone. Binding of
HPV-16 N-MAb H16.V5 to the hybrid VLP H11:16[FG 1 HI]
was equivalent to that observed using wild-type HPV-16
L1 VLPs (Fig. 2). Another HPV-16 N-MAb, H16.7E, bound
to VLPs of hybrid H11:16[38–65] (Table 2), defining an
additional type-specific epitope situated near the N-ter-
minus of HPV-16 L1. A second important observation
from these binding studies was that VLPs prepared from
several HPV11/16 hybrid L1 proteins retained conforma-
tionally dependent neutralizing epitopes for both HPV-11
and HPV-16 as determined by positive binding by sub-
and Rabbit Polyclonal Sera
Neutralization of
HPV-11 pseudovirionsa
Neutralization of
HPV-16 pseudovirionsa
.2000 N.T.c
N.T. .2500
.250 .100
.100 ,100
,100 .250
N.T. ,100
N.T. .250
N.T. .100
N.T. .250
N.T. .500
N.T. .250
N.T. .10,000
N.T. .100,000
N.T. N.T.
.100 N.T.
.100 N.T.
.100 N.T.
.100 N.T.
.100 N.T.
.100 N.T.
n the pseudovirion neutralization assay. Lowest dilution of sera and/orABLE 4
e MAbs
ctivity
and -16
and -16
and -16
lizing i
n).sets of HPV-11 and HPV-16 type-specific N-MAbs.
In order to gain a more complete understanding of the
330 CHRISTENSEN ET AL.nature and location of conformational neutralizing
epitopes on HPV-16 L1 VLPs, we developed a second
panel of 13 additional HPV-16 L1 VLP-reactive MAbs
(Table 1). These new reagents provided a valuable and
expanded set of probes that together with a panel of
HPV-11 VLP-reactive MAbs were able to detect a number
of different surface conformational sites on both wild-
type and hybrid VLPs (Table 1). For example, VLPs pre-
pared from the hybrid L1 construct H11:16[172–505] re-
tained neutralizing epitopes for both HPV-11 (MAbs
H11.B2, G5, and F1) and HPV-16 (MAbs H16.V5, E70, U14,
2F, 3A, 4A, 5A, and 6F). The reciprocal hybrid VLPs from
construct H16:11[171–505] retained a different set of neu-
tralizing epitopes for both HPV-11 (MAb H11.H3) and
HPV-16 (MAbs H16.7A and 9E).
Reconstruction of conformational neutralizing epitopes of
type-specific N-MAbs into an antigenically unrelated HPV
L1 backbone is the most convincing method to define the
critical regions of the epitope (Ludmerer et al., 1996). Neu-
tralizing sites are known to include hypervariable loop
structures of the intact virion (Ludmerer et al., 1996, 2000;
Roden et al., 1997; Chen et al., 2000; McClements et al.,
submitted for publication). We therefore proceeded to de-
velop a series of HPV-16 hypervariable loop replacements
into the HPV-11 L1 backbone for more detailed mapping of
the HPV-16 N-MAbs. The purpose of these replacements
was not to precisely map the critical amino acid contact
residues of individual N-MAbs, but to generate VLPs that
reconstructed major immunodominant neutralizing determi-
nants. Wild-type levels of binding for MAbs H16.V5, 1A, 2F,
5A, 6F, and H263.A2 were obtained when two hypervariable
regions of HPV-16 (aa 266–297 and 339–365) were replaced
into HPV-11 L1 (Tables 1 and 2 and Fig. 2). These observa-
tions indicate that the hypervariable regions contained
within aa 266–297 and 339–365 (FG and HI loops, respec-
tively; Chen et al., 2000) interact at the capsid surface and
represent an immunodominant conformational neutralizing
epitope. An alternative explanation is that the FG loop is the
predominant epitope recognized by MAbs H16.V5, 1A, 2F,
5A, 6F, and H263.A2, but there is an additional requirement
for the corresponding HPV-16 L1 HI loop of neighboring L1
molecules to maintain the conformational stability of the
HPV-16 FG loop on the surface of the VLP. This complex
epitope also appears to be a major component recognized
by antibodies in the sera of patients that have developed
responses to HPV-16 virions (Wang et al., 1997). A second
neutralizing epitope was defined by the hypervariable re-
gion encompassing aa 38–65 and was recognized by N-
MAb H16.7E (Table 1). Collectively, these data demon-
strated that noncontiguous hypervariable regions of HPV-16
L1 proteins were major conformationally dependent target
regions recognized by mouse N-MAbs. These data are
supported by epitope mapping studies of HPV-11 (Lud-
merer et al., 2000) and HPV-6 (McClements et al., 2001)
N-MAbs which also demonstrated that conformational neu-tralizing epitopes were located as noncontiguous hyper-
variable regions of L1 within assembled VLPs.
Not all HPV-16 L1 N-MAb epitopes were mapped us-
ing VLPs with hypervariable replacements. Those suc-
cessfully mapped included H16.V5, 1A, 2F, 5A, 6A, 7E,
and H263.A2. Five of the remaining 12 N-MAbs (H16.E70,
U4, 3A, 4A, and 9A) were unmapped (Table 1). Of special
interest was MAb H16.E70, which is known to require a
region encompassing the FG loop, in particular, residue
282 (Roden et al., 1997). Since H16.E70 bound to VLPs
prepared from construct H11:16[172–505], the data sug-
gest that additional regions between aa 172 and 505 are
required to retrieve full binding by this N-MAb.
Previous studies demonstrated that binding of MAbs
H16.V5 and E70 was lost upon mutation of aa 50 from
Phe 3 Leu (White et al., 1999). Phe50 is a conserved
amino acid which is positioned at the boundary of hy-
pervariable loop BC (Chen et al., 2000) and the side
chain of this amino acid may generate important inter-
actions with amino acid residues in the hypervariable FG
loop of the neighboring L1. We prepared a similar Phe3
Leu50 mutation in HPV-16 L1 and confirmed the obser-
vations of White et al. (1999). MAb reactivity to VLPs
prepared from this mutant L1 (Tables 1 and 2) demon-
strated that most HPV-16-reactive, conformationally de-
pendent MAbs no longer bound to this mutant VLP,
including MAbs H16.V5 and E70. However, our observa-
tions showed that reconstitution of the binding of MAb
H16.V5 (and several other HPV-16 reactive N-MAbs) re-
quired two noncontiguous regions (FG 1 HI loops) of L1
in the assembled capsid (Fig. 2 and Table 1) and that the
critical antigenic region did not encompass residue 50.
An explanation that is compatible with both these studies
is that the Phe3 Leu50 aa mutation produces VLPs that
have substantial surface structural changes at the level
of interaction between surface hypervariable loops tar-
geted by most N-MAbs (Chen et al., 2000). Local surface
structural changes imposed by such a mutation could
lead to more global changes in the antigenicity and
organization of the hypervariable loops, thereby disrupt-
ing the fine specificity of most of the conformational
neutralizing epitopes. Supporting this observation are
data by White et al. (1999) demonstrating that Leu50
mutant VLPs produced only low titers of polyclonal neu-
tralizing antibodies to HPV-16 virus. Additional support is
provided by studies from Ludmerer et al. (1996), who
showed that a substitution into HPV-11 L1 at another
position (aa 246) also reduced the binding of several
MAbs that targeted different conformational regions of
the capsid.
Hybrid L1 proteins containing large domain swaps
between HPV-11 and -16 were able to successfully as-
semble into VLPs, most likely because of the very high
level of homology of residues in the b-sheet domains of
these two L1 molecules. We have preliminary data indi-
cating that when domains of the more disparate CRPV
331HYBRID HPV L1 VLPsand HPV-11 L1 proteins were linked together, several of
these hybrid L1s failed to assemble into VLPs. In addi-
tion, when hypervariable loops FG and HI of HPV-16 L1
were replaced into the CRPV L1 backbone, we did not
observe any binding of the HPV-16 reactive MAbs such
as H16.V5 (data not shown). These preliminary data sug-
gest that the strategy of domain swapping and hyper-
variable loop replacements may be more successful
when L1 molecules that are closely related are used.
VLPs prepared from constructs H11:16[172–505], H16:
11[171–505], and H11:16[FG 1 HI] produced VLPs that
retained both HPV-11 and HPV-16 conformationally de-
pendent neutralizing epitopes (Table 1). It was important
therefore to test the antigenicity of such constructs with
respect to the induction of virus neutralizing antibodies.
Sera from rabbits immunized with these constructs in-
duced antibodies to both HPV types but produced neu-
tralizing antibodies predominantly to one HPV type (Ta-
ble 4). Construct H11:16[FG 1 HI], however, produced
neutralizing antibodies to both HPV-11 and -16. These
data demonstrate that two hypervariable regions at the
surface of VLPs interact to form a highly antigenic and
type-specific neutralizing epitope capable of inducing
neutralizing activity against HPV-16 despite the predom-
inance of HPV-11 L1 amino acids. These data also dem-
onstrate that in principle it is possible to create hybrid
VLPs which elicit neutralizing responses to distinct HPV
types.
MAbs obtained from mice immunized with VLPs from
construct H11:16[172–505] produced mixtures of type-
specific MAbs, several of which showed neutralizing
activity against HPV-11. All MAbs were selected initially
for binding to VLPs of the hybrid L1 construct. These data
indicate that the dual neutralizing activity of polyclonal
antisera that were generated against hybrid VLPs was
achieved by a mixture of type-specific HPV-11 and -16
neutralizing antibodies rather than from one set of HPV-
11/16 cross-reactive neutralizing antibodies.
In conclusion, the data reported in this study demon-
strated that hybrid VLPs may be useful “second-genera-
tion” HPV VLP vaccines for the induction of neutralizing
antibodies to antigenically unrelated HPV types. Such
hybrid VLPs will have to be carefully crafted in order to
trigger neutralizing responses to distinct types, and this
will require detailed knowledge of the major neutralizing
epitopes for the respective HPV types.
MATERIALS AND METHODS
Construction of hybrid and mutant HPV L1 sequences
Hybrid L1 constructs identified as H11:16[172–505]
and H16:11[171–505] (Fig. 1) were prepared by standard
molecular biological techniques. HPV-11 L1 was ob-
tained from the HPV-11 genome established in the athy-
mic mouse xenograft system (Kreider et al., 1985), and
HPV-16 L1 was obtained by PCR amplification from DNAextracted from CasKi cells. HPV-11 L1 was identical to
the published L1 sequence (Dartmann et al., 1986).
HPV-16 L1 contained the following aa differences from
the published L1 sequence (Seedorf et al., 1985):
202H 3 D; 235I 3 T; 266T 3 A; S inserted after 422T;
438D deleted. Hybrid L1 molecules were designed to
ensure that the two L1 fragments were joined in-frame to
generate a continuous L1 reading frame that retained
conserved features of all HPV L1 molecules.
Hypervariable regions of HPV-16 L1 were replaced
into the HPV-11 L1 backbone by first engineering unique
restriction enzyme sites into the HPV-11 L1 sequence at
the boundaries of the hypervariable regions of choice.
Site-directed mutagenesis was conducted using the
“QuikChange” site-directed mutagenesis kit (Stratagene,
La Jolla, CA) according to the manufacturer’s instruc-
tions. The unique restriction enzyme sites were designed
so as not to alter the existing amino acid sequence of the
HPV-11 L1. The hypervariable regions within the HPV-11
L1 gene were removed by restriction digestion and then
replaced by the complementary HPV-16 hypervariable
region (obtained by PCR amplification of HPV-16 L1) to
generate a plasmid containing the full-length, hybrid L1
gene. All constructs were sequenced to confirm that the
hypervariable replacements were completed and that
there were no PCR-introduced sequence errors. This
strategy provided opportunities to replace particular hy-
pervariable regions of HPV-11 L1 with the equivalent
hypervariable region of any HPV L1.
A mutant HPV-16 L1 in which amino acid Phe at posi-
tion 50 was converted to Leu (Leu50) was prepared by
site-directed mutagenesis as described above. VLPs
from this and all other hybrid L1 constructs were pre-
pared using recombinant baculovirus technology as de-
scribed below.
Construction of recombinant baculoviruses and
preparation of VLP
Recombinant baculoviruses producing wild-type and
hybrid L1 proteins were prepared as previously de-
scribed (Christensen et al., 1994). Hybrid/mutant L1
genes were excised from the cloning vector and ligated
into a baculovirus transfer vector (BD PharMingen, San
Diego, CA). Recombinant baculoviruses were prepared
by standard procedures (BD PharMingen). Infected Sf-9
cell lysates were tested by Western blotting for the pres-
ence of full-length L1 proteins for all constructs using the
cross-reactive anti-L1 MAb, H16.D9 (Christensen et al.,
1996a). VLPs were prepared as described and purified
by CsCl density gradient centrifugation (Christensen et
al., 1994). Fractions collected from the CsCl density gra-
dients were tested for L1 reactivity using a panel of
conformationally dependent MAbs as well as those that
recognized linear epitopes. A peak of ELISA activity at a
density of about 1.31 g/ml was used to operationally
332 CHRISTENSEN ET AL.define the status of the L1 as having assembled predom-
inantly into a VLP structure. Under these purification
conditions, smaller L1 assembly products such as cap-
someres do not band at 1.31 g/ml (Li et al., 1997).
Production of rabbit polyclonal and mouse
monoclonal antibodies
Monoclonal antibodies reactive to VLPs were pre-
pared using methods previously described (Christensen
et al., 1996a). In brief, VLPs from wild-type HPV-16 VLPs
(HPV-16 L1 was obtained by standard PCR amplification
from DNA extracted from CasKi cells) and two hybrid
VLPs prepared from constructs H11:16[172–505] and
H16:11[171–505] (see Fig. 1) were mixed with Freund’s
complete adjuvant and injected subcutaneously into fe-
male BALB/c mice. Two weeks after immunization, drain-
ing lymph node cells were collected as a source of
immune cells for the production of hybridomas. Rabbit
polyclonal antibodies reactive to VLPs for HPV-16 and
HPV-11 L1 VLPs and to VLPs for the hybrid L1s from
constructs H11:16[172–505], H16:11[171–505], and H11:
16[FG 1 HI] were prepared by subcutaneous immuniza-
tion of rabbits with VLPs (200 mg per rabbit per immuni-
zation) mixed in complete Freund’s adjuvant for the first
immunization and in incomplete Freund’s adjuvant for
the booster immunizations. Sera were prepared from
immunized rabbits after the first or second booster in-
jection and stored at 4°C.
ELISAs using either intact or denatured VLPs were
prepared to test MAb and Pab reactivities as previously
described (Christensen et al., 1994). MAbs were tested
as cell culture supernatants at dilutions of 1:50 or at
10-fold dilutions when prepared as ascites fluids in
BALB/c mice. Sera were tested at 10-fold dilutions
against various VLP antigens and titers calculated as the
dilution of sera that gave 50% of the maximum optical
density (OD) readings using a Dynatech plate reader at a
wavelength of 410 nm. All antibody dilutions were tested
in duplicate wells and means and standard deviations
(SD) were calculated.
Virus neutralization assays
Two in vitro neutralization assays were used in this
study. The first neutralization assay used HPV-11 and -16
L1 pseudovirions to test neutralization of the MAbs and
PAbs (Yeager et al., 2000). In brief, HPV-11 and -16
pseudovirions coupled to a BLAM reporter gene were
incubated with dilutions of MAb and PAb and then added
to cultures of human cervical carcinoma C33A cells.
After a 2-day culture period, intracellular BLAM activity
was quantified using a Cytofluor (PerSeptive Biosystems,
Framingham, MA) multiwell plate reader as described
(Yeager et al., 2000).The RT-PCR transient infection assay originally de-
scribed by Smith et al. (1993, 1995) with some modifica-tions (Ludmerer et al., 2000) was also used to assess
neutralization of HPV-11. Infectious HPV-11 virions were
obtained using the athymic mouse xenograft system
(Kreider et al., 1985). Primers were designed to detect
spliced E1^E4 viral transcripts after infection of human
A431 cells as previously described (Ludmerer et al.,
2000). For infection, 1 ml of virus stock was added to
cultures of A431 cells in 6-well plates and cultured for 4
days. Cells were harvested by lysis in 1 ml Trizol reagent
(Gibco BRL, Grand Island, NY) and then RNA purified for
RT using the GeneAmP RNA PCR kit (Perkin–Elmer, Fos-
ter City, CA) as described by the manufacturer. Viral
spliced products from PCRs were detected as ethidium
bromide-stained bands following separation on agarose
gels. In addition, the viral origin of the PCR products was
confirmed by cloning and sequencing.
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